Cancer Travel Insurance News by AllClear Travel

News Article: New drug for prostate cancer sufferers can extend life by five months

September 2012

A new drug for men with advanced prostate cancer that has become resistant to standard hormones appears to give those who have trialled it (them) five months' extra life.

Trials on nearly 1200 patients showed men taking enzalutamide survived for more than 18 months compared with less than 14 months for those on a placebo.

Enzalutamide, which was developed by British scientists at the Institute of Cancer Research and the Royal Marsden Hospital in London, is one of four discoveries in the past two years that appear to show that they can significantly extend life.

Professor Alan Ashworth, chief executive of the ICR, said cancer research in the UK was finally delivering new treatments for men with advanced prostate cancer.

The drug could be licensed for use by British patients early next year.

AllClear is a specialist insurance company that provides travel insurance for people with cancer, including prostate cancer travel insurance